Vigonvita Life Sciences Co., Ltd. (VIGONVITA-B) received comprehensive shareholder backing at its postponed 2026 annual general meeting (AGM) held on 30 June in Suzhou, cementing a broad corporate governance overhaul while renewing mandates for capital management.
Shareholder turnout and voting results • Of the company’s 167.60 million issued shares, 117.50 million—equal to 70.11% of share capital—were voted by poll at the meeting. • All nine routine resolutions, including the 2025 annual report, board and independent director work reports, final accounts, and a 2025 profit distribution plan, secured 100% approval. • Shareholders also granted unanimous consent to appoint HLB Hodgson Impey Cheng Limited as external auditor for 2026 and approved updated rules of procedure for shareholder and board meetings.
Board re-election and governance changes • Using cumulative voting, Dr. Tian Guanghui and Dr. Hu Tianwen were re-elected as executive directors; Mr. Liu Haoxuan secured the sole non-executive director seat; and Dr. Ju Dianwen, Ms. Cao Xinwen and Dr. Xu Hongxi were returned as independent non-executive directors. All directors will serve three-year terms beginning 30 June 2026. • Dr. Tian Guanghui was simultaneously appointed chairman of the second board session and confirmed as general manager, while Dr. Hu Tianwen and Dr. Wang Zhiqiang became deputy general managers. Ms. Guo Ting was named board secretary and Ms. Yao Zheng the finance head. • Committee assignments took effect immediately: – Audit Committee: chaired by independent director Ms. Cao Xinwen, with Dr. Xu Hongxi and Dr. Ju Dianwen as members. – Nomination Committee: chaired by Dr. Tian Guanghui, with Dr. Xu Hongxi and Ms. Cao Xinwen. – Remuneration & Appraisal Committee: chaired by Dr. Xu Hongxi, with Dr. Hu Tianwen and Dr. Ju Dianwen.
Supervisory Committee abolished Shareholders approved (93.89% in favour) a special resolution eliminating the Supervisory Committee and amending the Articles of Association accordingly. All former supervisors confirmed no disagreement with the board and no outstanding matters requiring shareholder attention.
Capital authorisations Two special resolutions passed with 100% support: 1. A general mandate allowing the board to issue additional H-shares. 2. A general mandate permitting the repurchase of H-shares.
These mandates enhance the board’s flexibility in future capital management.
With the AGM decisions now effective, Vigonvita Life Sciences enters its second board term under a streamlined governance structure and refreshed senior management lineup.
Comments